SCHEMBL8326880

SCHEMBL8326880

O=c1[nH]c(=O)n([C@@H]2CC(O)[C@H](COC(c3ccccc3)(c3ccccc3)c3ccccc3)O2)cc1F

nearest known ligand 0.64

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
TYMP P19971 1/20 0.58
HSP90AA1 P07900 1/20 0.58
TYMS P04818 6/20 0.55
ALOX12 P18054 1/20 0.50
ADRA1A P35348 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8326876 1.00 LMNA (0.64) LMNASMN1; SMN2TYMPHSP90AA1TYMS
SCHEMBL3341212 0.93 TYMS (0.56) LMNASMN1; SMN2TYMPHSP90AA1TYMS
SCHEMBL7703578 0.93 TYMS (0.56) LMNASMN1; SMN2TYMPHSP90AA1TYMS
SCHEMBL3341208 0.93 TYMS (0.56) LMNASMN1; SMN2TYMPHSP90AA1TYMS
SCHEMBL7703575 0.93 TYMS (0.56) LMNASMN1; SMN2TYMPHSP90AA1TYMS
SCHEMBL9227960 0.89 LMNA (0.67) LMNASMN1; SMN2TYMPTYMSALOX12
SCHEMBL9227962 0.89 LMNA (0.67) LMNASMN1; SMN2TYMPTYMSALOX12
SCHEMBL10692639 0.88 TK1 (0.64) TYMPTYMS
SCHEMBL10446716 0.88 POLB (0.58) TYMP
SCHEMBL6334503 0.88 POLB (0.58) TYMP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5869464-A HAVING LOW TOXICITY, SUSTAINING LOW CONCENTRATION IN BLOOD FOR EXTENDED PERIOD TAIHO PHARMACEUTICAL CO. LTD. (JP) 1999-02-09 US disclosed
EP-0686641-B1 2'-DEOXY-5-FLUOROURIDINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR DRUG TAIHO PHARMACEUTICAL CO LTD (JP) 1998-08-26 EP disclosed
EP-0323441-B1 5-Fluorouracil derivatives OTSUKA PHARMA CO LTD (JP) 1996-04-24 EP disclosed
EP-0686641-A1 2'-DEOXY-5-FLUOROURIDINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR DRUG TAIHO PHARMACEUTICAL CO., LTD. (JP) 1995-12-13 EP disclosed
EP-0247381-B1 5-FLUROROURACIL DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-08-04 EP disclosed
EP-0331032-B1 2'-DEOXY-5-FLUOROURIDINE DERIVATIVES TAIHO PHARMACEUTICAL CO., LTD. (JP) 1993-04-28 EP disclosed
US-5155113-A Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-10-13 US disclosed
EP-0180188-B1 A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-04-15 EP disclosed
US-5049551-A Antitumor UBE INDUSTRIES, LTD. (JP) 1991-09-17 US disclosed
US-5047521-A Anticarcinogenic agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-09-10 US disclosed
US-4992534-A Anticarcinogenic agents with better water solubility, low toxicity, absorption and stability OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-02-12 US disclosed
US-4983609-A Anticancer agents OTSUKA PHARMACEUTICAL (JP) 1991-01-08 US disclosed
EP-0400610-A1 5-Fluorouracil derivatives UBE INDUSTRIES, LTD. (JP) 1990-12-05 EP disclosed
EP-0331032-A1 2'-Deoxy-5-fluorouridine derivatives TAIHO PHARMACEUTICAL CO., LTD. (JP) 1989-09-06 EP disclosed
US-4864021-A ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-09-05 US disclosed
EP-0323441-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-07-05 EP disclosed
EP-0303269-A2 2'-Deoxy-5-fluorouridine derivatives, process for preparing the same and the use thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-02-15 EP disclosed
EP-0247381-A2 5-flurorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-12-02 EP disclosed
EP-0180897-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-14 EP disclosed
EP-0180188-A2 A composition for increasing the anti-cancer activity of an anti-cancer compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-07 EP disclosed